Rare disease Background:
Background
Chryseobacterium gleum, of the family Flavobacterium, is a nonfermentative, gram-negative bacillus. It primarily causes infections such as urinary tract infections and pneumonia, largely in immunocompromised patients and neonates [1] . The genus' ability to thrive in aqueous environments and form biofilms makes it a potential pathogen in patients on ventilators and in those with central lines, thus contributing to healthcareassociated and device-associated infections [2] . Their intrinsic resistances to broad-spectrum agents, including carbapenems, aminoglycosides, and colistin, are of further concern [3].
The SENTRY Antimicrobial Surveillance Program first identified C. gleum as a medically relevant pathogen; however, it was the least frequently isolated species of the Chryseobacterium genus, with only 2 identified strains in 16 countries over the 5-year study period [4] . While remarkably rare, a growing number of case reports demonstrate its isolation in respiratory cultures in Europe and Southeast Asia [5] . Here, we describe the case of a patient admitted in the United States with multifocal community-acquired pneumonia later found to have C. gleum isolated from a sputum sample and successfully treated with trimethoprim-sulfamethoxazole.
Case Report
A 61-year-old man with a history of supra-glottic laryngeal cancer (T2M0N0) status after chemoradiation 3 years prior presented to the Emergency Department with a 2-day history of fatigue, weakness, chills, and altered mental status. His past history was relevant for chronic obstructive pulmonary disease (COPD) not on home oxygen, stroke without dysphagia, hyperlipidemia, and a post-traumatic right above-knee leg amputation from a gunshot wound over a decade ago that was treated and otherwise uncomplicated.
Initial vital signs showed the patient to be afebrile, hypoxic, hypotensive, and tachycardic. The patient was visibly short of breath and tachypneic on physical examination. Pulse oxygenation saturation was 86% on non-rebreather. He was cachectic, with temporalis muscle wasting. The results of a neck exam were unremarkable. Bilateral rhonchi were present on lung examination. An initial chest radiograph demonstrated diffuse bilateral infiltrates. Point-of-care testing for Influenza A was positive. The patient was started on oseltamivir and broad-spectrum antibiotics, including ceftriaxone, azithromycin, and vancomycin, to cover for community-acquired pneumonia, as well as possible post-influenza staphylococcal pneumonia. He was placed on bi-level positive airway pressure (BiPAP) after desaturating to 76% on non-rebreather, and was admitted to the medical intensive care unit for further management.
Blood cultures obtained on initial admission showed no growth throughout the admission.
On the second day of admission, the patient was taken off BiPAP and placed on a high-flow nasal cannula. Vancomycin was discontinued on hospital day 3, and the patient was transferred to the medical floor. Shortly after transfer, he had a desaturation episode requiring use of a VentiMask for oxygen support. He was afebrile at this time, but was found to have new-onset leukocytosis (12.1 K/mm 3 with neutrophilic predominance of 10.5 K/mm 3 ). A physical exam demonstrated bilateral crackles and bronchial breathing without evidence of edema. Respiratory sputum cultures obtained at this time grew numerous Chryseobacterium gleum and few Stenotrophomonas (Xanthomonas) maltophilia. Urine streptococcal pneumonia antigen was also found to be positive. The patient continued to be hypoxic and developed a fever. A repeat white blood cell count had increased to 15.7 K/mm 3 . Azithromycin and ceftriaxone were discontinued after 8 days of continuous treatment, and trimethoprim-sulfamethoxazole was initiated due to the isolation of Chryseobacterium gleum in the respiratory culture. Two days later, the patient was improving, afebrile, and saturating well on nasal cannula. He was discharged home on the fourth day of trimethoprim-sulfamethoxazole therapy on nasal cannula to complete a total 7-day course of therapy. Upon post-hospital discharge follow-up, the patient was no longer reporting respiratory symptoms and did not require supplemental oxygen with nasal cannula. 
Discussion
Documented risk factors in adults for C. gleum include immunocompromised state, a prolonged hospitalization, and medical intensive care unit stay (greater than 21 days). The use of BiPAP and VentiMask have been described, with the hypothesis that these devices may harbor C. gleum. Exposure to broadspectrum antibiotics, including treatment with vancomycin and ceftriaxone, has also been noted [6] . Our patient had several of these risk factors, including possible immune function compromise secondary to his malnourished state, antibiotic exposure, and use of BiPAP and VentiMask during portions of his admission. He did not, however, have an indwelling catheter or a prolonged hospital or medical intensive care unit stay. It is a possibility that our patient was exposed to C. A true pathogen must be differentiated from a colonizer. Colonization occurs when microbes exist on a carrier without causing infection [7] , and is common in the upper respiratory tract, where large quantities of different bacteria exist [8] . Repeating a sample collection supports the notion that an isolated microbe is causing a patient's infection, but no specific guidelines for repeat cultures exist in the literature [5] . Although our patient's sputum showed numerous C. gleum, only 1 sample was obtained throughout his stay. The patient's worsening clinical picture, despite broad-spectrum antibiotics for over a week, his rapid improvement following trimethoprimsulfamethoxazole therapy, coupled with the various risk factors for non-fermentative gram-negative bacilli, collectively support the theory that the C. gleum isolate was pathogenic.
The isolated strain showed susceptibility to piperacillin-tazobactam and trimethoprim-sulfamethoxazole, but was otherwise resistant to the remaining tested antibiotics as listed in Table 1 , with breakpoint diffusions based on Clinical and Laboratory Standards Institute (CLSI) guidelines for non-fermentative gram-negative bacilli protocol. While resistance to carbapenems, aminoglycosides, and colistin is well documented within the genus, the isolate's resistance to ceftazidime and cefepime are noteworthy and concerning. A summary of other available case reports documenting susceptibilities and treatment of respiratory C. gleum pathogenic isolates is described in Table 2 . Currently, there are no standardized break points for Chryseobacterium spp. in European Committee on Antimicrobial Susceptibility Testing (EUCAST) or CLSI guidelines for disc diffusion susceptibility testing, necessitating laboratories to adopt disc diffusion protocols for other classes of organisms including Staphylococcus spp. or non-fermentative gram-negative bacilli protocol [9, 10] .
To the best of our knowledge, our decision to treat a respiratory isolate of C. gleum solely with trimethoprim-sulfamethoxazole is a first in the literature. While the organism has consistently shown susceptibility to trimethoprim-sulfamethoxazole in various case reports, fluoroquinolones such as levofloxacin and ciprofloxacin or piperacillin-tazobactam (or a combination of these agents) are typically used for therapy (see Table 2 ). For this patient, both organisms isolated from the sputum culture were shown to be susceptible to trimethoprim-sulfamethoxazole. Rapid clinical improvement following treatment supports the diagnosis of C. gleum pneumonia.
Conclusions
C. gleum should be considered in patients with pneumonia who fail to respond to treatments for common pathogens and who have additional risk factors, including extended medical intensive care unit stay, immunocompromised state, indwelling catheter, antibiotic exposure, and mechanical ventilation. Sputum culture for identification can be helpful. When isolated, C. gleum should be considered as a possible pathogen and appropriate treatment initiated. The literature has consistently shown effective treatment to include fluoroquinolones, piperacillin-tazobactam, and trimethoprim-sulfamethoxazole.
